Edwards Lifesciences Corporation
Edwards Lifesciences to Sell Critical Care to BD for $4.2 Billion
Summary
On June 3, 2024, Edwards Lifesciences Corporation announced it entered into a definitive agreement to sell its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billion in cash. This decision replaces the previously planned spin-off of the Critical Care business. The transaction is expected to close by the end of 2024, pending antitrust and foreign investment approvals. Edwards plans to use the after-tax cash proceeds to fund strategic growth investments in structural heart innovations and other therapeutic areas.
Profitelligence Alerts
Get alerts for EW
Be first to know when Edwards Lifesciences Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.
Official SEC Documents
Advertisement